Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Aug;101(2):416-417.
doi: 10.4269/ajtmh.19-0224.

Characterization of Plasmodium vivax pvmdr1 Polymorphisms in Isolates from Mangaluru, India

Affiliations
Observational Study

Characterization of Plasmodium vivax pvmdr1 Polymorphisms in Isolates from Mangaluru, India

Costanza Tacoli et al. Am J Trop Med Hyg. 2019 Aug.

Abstract

India accounts for approximately half of the global Plasmodium vivax cases, but information as to the presence of chloroquine (CQ) resistance is scarce. In an observational study in Mangaluru, south-western India, of 116 vivax malaria patients analyzed, 89.5% (102/114) had cleared parasitemia on days two or three of CQ treatment. Two remaining patients presented on days four and five without parasitemia. One hundred eight isolates of these 116 patients were successfully sequenced for pvmdr1 polymorphisms. Eight non-synonymous polymorphisms but no wild-type isolate were detected. Ten pvmdr1 haplotypes were observed with mutations T958M and F1076L occurring in all isolates, whereas the candidate CQ resistance marker Y976F was present in one isolate only. Pvmdr1 polymorphisms were not associated with early parasite clearance. The high proportion of early parasite clearance and the virtual absence of pvmdr1 Y976F and of sextuple pvmdr1 mutants suggest that CQ in the study area is still sufficiently effective. However, the abundance of pvmdr1 mutations in the local parasite population warrants monitoring.

PubMed Disclaimer

References

    1. World Health Organization , 2017. WHO Malaria Report. Available at: https://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf/. Accessed March 1, 2019.
    1. Anvikar AR, Shah N, Dhariwal AC, Singh G, 2016. Epidemiology of Plasmodium vivax malaria in India. Am J Trop Med Hyg 95: 108–120. - PMC - PubMed
    1. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, 2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14: 982–991. - PMC - PubMed
    1. Suwanarusk R, et al. 2008. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis 198: 1558–1564. - PMC - PubMed
    1. Nyunt MH, Han JH, Wang B, Aye KM, Aye KH, Lee SK, Htut Y, Kyaw MP, Han KT, Han ET, 2017. Clinical and molecular surveillance of drug resistant vivax malaria in Myanmar (2009–2016). Malar J 16: 117. - PMC - PubMed

Publication types

LinkOut - more resources